Inhaltsbereich
| 10 Einträge |
Seite 1 / 1
 Druckansicht
|
| Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. |
| Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A |
| European urology. 2020 Jul 2. pii: S0302-2838(20)30472-3. doi: 10.1016/j.eururo.2020.06.043 |
| PMID: 32624288 |
| Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. |
| Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A |
| European urology. 2020 Jul 2. pii: S0302-2838(20)30507-8. doi: 10.1016/j.eururo.2020.06.047 |
| PMID: 32624281 |
| Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. |
| Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A |
| European urology oncology. 2021 Jun 24. pii: S2588-9311(21)00118-8. doi: 10.1016/j.euo.2021.06.003 |
| PMID: 34176768 |
| A randomized study of pomalidomide vs. placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion-dependence. |
| Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP |
| Leukemia. pii: leu2016300. doi: 10.1038/leu.2016.300 |
| PMID: 27773929 |
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. |
| Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC |
| Leukemia. 2017 Jun 8. pii: leu2017175. doi: 10.1038/leu.2017.175 |
| PMID: 28592889 |
| The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal. |
| Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winklerhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, van den Bent M, Wen PY, Bendzus M, Weller M |
| Neuro-oncology. 2019 Jan 23. pii: 5306141. doi: 10.1093/neuonc/noz024 |
| PMID: 30715514 |
| Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. |
| Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ |
| Leukemia. 2020 Aug 7. doi: 10.1038/s41375-020-0979-6. pii: 10.1038/s41375-020-0979-6 |
| PMID: 32770086 |
| Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. |
| Le Rhun E, Devos P, Weller J, Seystahl K, Mo F, Compter A, Berghoff AS, Jongen JLM, Wolpert F, Rudà R, Brandsma D, van den Bent M, Preusser M, Herrlinger U, Weller M |
| Neuro-oncology. 2020 Dec 23. pii: 6046195. doi: 10.1093/neuonc/noaa298 |
| PMID: 33367859 |
| Prognostic factors in leptomeningeal metastases. |
| Le Rhun E, Devos P, Weller J, Seystahl K, Mo F, Compter A, Berghoff AS, Jongen JLM, Wolpert F, Rudà R, Brandsma D, van den Bent M, Preusser M, Herrlinger U, Weller M |
| Neuro-oncology. 2021 Apr 8. pii: 6217329. doi: 10.1093/neuonc/noab051 |
| PMID: 33830220 |
| Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. |
| Le Rhun E, Devos P, Winklhofer S, Lmalen H, Brandsma D, Kumthekar P, Castellano A, Compter A, Dhermain F, Franceschi E, Forsyth P, Furtner J, Galldiks N, Pérez-Larraya JG, Gempt J, Hattingen E, Hempel JM, Lukacova S, Minniti G, O'Brien B, Postma TJ, Roth P, Rudà R, Schaefer N, Schmidt NO, Snijders TJ, Thust S, van den Bent M, van der Hoorn A, Vogin G, Smits M, Tonn JC, Jaeckle K, Preusser M, Glantz M, Wen PY, Bendzsus M, Weller M |
| Neuro-oncology. 2022 Feb 14. pii: 6528471. doi: 10.1093/neuonc/noac043 |
| PMID: 35157772 |
| 10 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
